The number of new COVID-19 cases in the U.S. is dropping as the omicron wave wanes in many places, but some parts of the country lag behind.

"As a nation, it looks like we've kind of gotten to the peak and are now starting on the decline, but it's very uneven," explains Dr. Gregory Poland, head of Mayo Clinic's Vaccine Research Group. "That's what's happening in the big Northeast cities, and maybe in L.A., for example. But if you look at the rest of the nation, it's not clear that they have peaked yet."

And on the heels of the latest surge, a new omicron subvariant — BA.2 — is emerging. Early indications are that the new subvariant may be more transmissible, but it does not appear to cause more severe disease than the original omicron strain.

Mayo experts, including Dr. Poland, continue to urge COVID-19 vaccinations and boosters as the best defense against the latest variants.

"By getting two doses of vaccine and a booster, or a dose of Johnson & Johnson and a booster, you move yourself into a category of maximal protection such that if you have a normal immune system, you are probably going to have trivial or even asymptomatic disease if you get infected with COVID-19," explains Dr. Poland.

On the Mayo Clinic Q&A podcast, Dr. Poland discusses the latest information on COVID-19 and answers listener questions.
_______________________________________
For the safety of its patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was either recorded prior to COVID-19 or recorded in a nonpatient-care area where social distancing and other safety protocols were followed.
Information in this post was accurate at the time of its posting. Due to the fluid nature of the COVID-19 pandemic, scientific understanding, along with guidelines and recommendations, may have changed since the original publication date.

Dr. Poland is a paid scientific adviser for Johnson & Johnson/Janssen Global Services LLC. Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co., Medicago, GlaxoSmithKline, Sanofi Pasteur, Emergent Biosolutions, Dynavax, Genentech, Eli Lilly and Company, Kentucky Bioprocessing, Bavarian Nordic, AstraZeneca, Exelixis, Regeneron, Janssen, Vyriad, Moderna, and Genevant Sciences, Inc. Dr. Poland holds patents related to vaccinia, influenza, and measles peptide vaccines. Dr. Poland has received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.

For more information and all your COVID-19 coverage, go to the Mayo Clinic News Network and mayoclinic.org.
Learn more about tracking COVID-19 and COVID-19 trends.

свернуть